Outcome of Second Allogeneic Hematopoietic Cell Transplantation (AlloHCT2) in Patients with Acute Lymphoblastic Leukemia (ALL)

The outcome of patients with ALL relapsing after AlloHCT1 is poor. A second transplant remains a potential curative option in a subset of patients. Patients who relapse within the first year post AlloHCT1 should preferably be enrolled in a clinical trial of novel therapies.

Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Monzr M. Al Malki, Ibrahim Aldoss, Tracey Stiller, Ryotaro Nakamura, David S. Snyder, Stephen J. Forman, Vinod Pullarkat Tags: Original Study Source Type: research